secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001213900-24-090831
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

CERO Therapeutics receives Nasdaq delisting notice; stock price at $0.10 or less
--------------------------------------------------------------------------------

- Nasdaq determined to delist CERO common stock due to closing bid price ≤$0.10 for 10 consecutive days.
- Company has until Oct 31, 2024 to appeal; hearing request will stay suspension pending panel decision.
- Company plans to propose reverse stock split at Nov 11 special meeting to regain compliance, but approval uncertain.
- Prior Bid Price Cure Period until Jan 15, 2025 is rendered unavailable by Low Priced Stocks Rule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024090831/0001213900-24-090831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024090831/ea0218621-8k_cerothe.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-090831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer